AZD8965 for Pulmonary Fibrosis

(ARGiNAUT Trial)

This trial tests a new treatment called AZD8965 for individuals with idiopathic pulmonary fibrosis (IPF), a lung disease that makes breathing difficult. The study will evaluate the safety and effectiveness of different doses of AZD8965 compared to a placebo (a substance with no active medication). Participants may be taking other IPF medications or none at all. This trial might suit someone diagnosed with IPF who is either on stable medication or not taking any IPF treatment. As a Phase 2 trial, the research focuses on assessing the treatment's effectiveness in an initial, smaller group, offering participants a chance to contribute to significant advancements in IPF treatment.

Research has shown that AZD8965 has undergone safety testing in several studies. In trials involving 1,299 patients with idiopathic pulmonary fibrosis—a lung disease that causes scarring and makes breathing difficult—the treatment was generally well-tolerated, with most participants experiencing no serious side effects.

Another study tested various doses of AZD8965 in healthy individuals and found the treatment safe across different dose levels. While some side effects occurred, they were not serious for most participants.

AZD8965 is unique because it targets pulmonary fibrosis in a way that existing treatments, such as antifibrotic medications like pirfenidone and nintedanib, do not. While standard treatments slow disease progression by inhibiting fibrosis, AZD8965 is designed to specifically target and modulate the underlying pathways involved in the fibrotic process. Researchers are excited about the potential for AZD8965 to offer more effective management of pulmonary fibrosis by addressing its root causes, potentially leading to better patient outcomes. Additionally, the trial includes various dosing levels, which allows researchers to fine-tune the optimal dose for maximum efficacy with minimal side effects.

Research has shown that AZD8965 may help treat idiopathic pulmonary fibrosis (IPF). In studies with mice, AZD8965 significantly reduced harmful substances and collagen buildup in the lungs, which are major issues in IPF. Earlier studies with humans found that AZD8965 is safe and well-tolerated. Similar drugs, such as nintedanib and pirfenidone, have effectively slowed the decline of lung function in IPF patients. These findings suggest that AZD8965 could help manage IPF by reducing lung damage and preserving lung function.¹³⁶⁷⁸